Aclaris' Cash, Cash Equivalents And Marketable Securities Of $149.9M As Of June 30, 2024 And $26.5M From Sale Of Olumiant Royalties And Milestones Will Be Sufficient To Fund Its Operations Into 2028
Portfolio Pulse from Benzinga Newsdesk
Aclaris Therapeutics has reported having $149.9 million in cash, cash equivalents, and marketable securities as of June 30, 2024. Additionally, the company has secured $26.5 million from the sale of Olumiant royalties and milestones. These funds are expected to be sufficient to support its operations until 2028.
August 07, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Aclaris Therapeutics has $149.9 million in cash and $26.5 million from Olumiant royalties, which will fund its operations until 2028.
The substantial cash reserves and additional funds from Olumiant royalties provide a strong financial foundation for Aclaris Therapeutics, reducing the risk of liquidity issues and supporting long-term operational stability. This is likely to be viewed positively by investors.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100